Amylyx Pharmaceuticals (AMLX) Depreciation and Depletion (2021 - 2026)

Amylyx Pharmaceuticals' Depreciation and Depletion history runs 6 years deep, the most recent figure standing at $98000.0 for Q1 2026.

• In Q1 2026, Depreciation and Depletion fell 37.18% year-over-year to $98000.0; the TTM figure through Mar 2026 stood at $467000.0 (down 37.32% YoY), while the FY2025 annual figure was $525000.0, down 41.92% from the prior year.
• Depreciation and Depletion was $98000.0 for Q1 2026 at Amylyx Pharmaceuticals, down from $108000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $315000.0 in Q1 2024 to a low of $35000.0 in Q1 2022.
• Historically, Depreciation and Depletion has averaged $182470.6 across 5 years, with a median of $165000.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion surged 1550.0% in 2022, then slumped 50.48% in 2025.
• A 5-year view of Depreciation and Depletion shows it stood at $182000.0 in 2022, then surged by 65.38% to $301000.0 in 2023, then plunged by 46.84% to $160000.0 in 2024, then sank by 32.5% to $108000.0 in 2025, then retreated by 9.26% to $98000.0 in 2026.
• The last three Depreciation and Depletion figures came in at $98000.0 (Q1 2026), $108000.0 (Q4 2025), and $120000.0 (Q3 2025), per Business Quant data.